Company intelligence / Profile preview

Samsung Epis Holdings

Incheon, South Korea
Ownership
Private
Development stage
Other
01

Overview

Samsung Epis Holdings was formed as a spin-off from Samsung Biologics in 2025 and is now the parent company overseeing Samsung Bioepis and Epis NexLab, both focused on biosimilars, innovative biologics and platform technologies; its main subsidiary Samsung Bioepis has commercialized 11 biosimilars and aims to expand to over 20 assets, covering immunology, oncology, ophthalmology, and hematology, with strong clinical evidence and global access

Therapeutic areas
OncologyImmunologyOphthalmologyGastroenterology
Modalities
Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatePeptidesBiologic
Industry
Pharma
02

Partnerships

Biogen (development and commercialization)Organon (commercialization, ex-US Merck spinoff)SandozTevaTakeda (co-development of novel biologics)3SBio (regional China)CBC Group/AffaMed Therapeutics (regional China)Mundipharma (Hong Kong and Taiwan)BionovisBio-Manguinhos (Brazil)

Beyond the preview

Go deeper on Samsung Epis Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samsung Epis Holdings.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call